People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ensoma, Inc. | — | Biotechnology | Series D+ | $169.6M | $2.3B | 2022 |
| Rallybio Holdings, LLC | — | Other Health Care | Series D+ | $157.8M | $69.6M | 2024 |
| Entrada Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $150.9M | $3.3B | 2021 |
KUSH M. PARMAR at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KUSH M. PARMAR on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 3 | 10 |
| Todd Foley | 1 | 12 |
| Ketan Patel | 1 | 10 |
| Tim Shannon | 1 | 9 |
| STEPHEN KNIGHT | 1 | 6 |
| Ron Hunt | 1 | 4 |
| Ronald M. Hunt | 1 | 4 |
| Louis Tartaglia | 1 | 3 |
| Christine Brennan | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| Nihal Sinha | 1 | 2 |
| Christine A. Nash | 1 | 2 |
| Tim W. Shannon | 1 | 2 |
| Mario Saltarelli | 1 | 2 |
| Lucian Iancovici | 1 | 2 |
| Emile Nuwaysir | 1 | 2 |
| John F. Crowley | 1 | 2 |
| John Crowley | 1 | 2 |
| Ketan W. Patel | 1 | 2 |
| Albert Seymour | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.